A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema.
Two million Americans suffer from pulmonary emphysema, costing $2.5 billion/year and contributing to 100,000 deaths/year. Emphysema is thought to result from an imbalance between elastase and endogenous inhibitors of elastase, leading to tissue destruction and a loss of alveoli. Decades of research have still not resulted in an effective treatment other than stopping cigarette smoking, a highly addictive behavior. On the basis of our previous work, we hypothesize that small molecule inhibitors of human neutrophil elastase are ineffective because of rapid clearance from the lungs. To develop a long-acting elastase inhibitor with a lung pharmacodynamic profile that has minimal immunogenicity, we covalently linked an elastase inhibitor, similar to a trifluoro inhibitor that was used in clinical trials, to a 25-amino-acid fragment of human surfactant peptide B. We used this construct to prevent human neutrophil elastase-induced emphysema in a rodent model. The elastase inhibitor alone, although in a 70-fold molar excess to elastase in a mixture with <0.6% residual elastase activity, provided no protection from elastase-induced emphysema. Covalently combining an endogenous peptide from the target organ with a synthetic small molecule inhibitor is a unique way of endowing an active compound with the pharmacodynamic profile needed to create in vivo efficacy.
Paka Pulmonary Pharmaceuticals, Acton, MA 01720, USA. frankguarnieri@yahoo.com
Frank
F
Guarnieri
Jean L
JL
Spencer
Edgar C
EC
Lucey
Matthew A
MA
Nugent
Phillip J
PJ
Stone
D000818:Animals; D004195:Disease Models, Animal; D004646:Emphysema / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D015394:Molecular Structure; D010196:Pancreatic Elastase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010455:Peptides / Q000138:chemical synthesis / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000138:chemical synthesis / Q000627:therapeutic use*; D013379:Substrate Specificity; D013501:Surface-Active Agents / Q000138:chemical synthesis / Q000627:therapeutic use*
D010455:Peptides; D011480:Protease Inhibitors; D013501:Surface-Active Agents; D010196:Pancreatic Elastase